Novel codon-optimized mini-intronic plasmid for efficient, inexpensive and xeno-free induction of pluripotency

Diecke, Sebastian; Lu, Jiamiao; Lee, Jaecheol; Termglinchan, Vittavat; Kooreman, Nigel G.; Burridge, Paul W.; Ebert, Antje; Churko, Jared M.; Sharma, Arun; Kay, Mark A.; Wu, Joseph C.

doi:10.1038/srep08081

Cited by 55 publications

(59 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fibroblasts were dissociated using TrypLE Express (ThermoFisher Scientific) and 1x10 6 fibroblasts were resuspended in electroporation buffer (Neon system, ThermoFisher Scientific). Cells were transfected with a codon-optimized mini-intronic plasmid (coMIP) containing the four reprogramming factors Oct4, Sox2, c-Myc, and KLF4 (Diecke et al, 2015). After transfection, cells were plated on irradiated mouse embryonic feeder (MEF) cells and cultured in DMEM with 15% FBS, 1x NEAA, and 10 ng/ml murine leukemia inhibiting factor (mLIF; EMD Millipore, MA, USA).…”

Section: Star Methodsmentioning

confidence: 99%

Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo

et al. 2018

Self Cite

View full text Add to dashboard Cite

Cancer cells and embryonic tissues share a number of cellular and molecular properties, suggesting that induced pluripotent stem cells (iPSCs) may be harnessed to elicit anti-tumor responses in cancer vaccines. RNA-sequencing revealed that human and murine iPSCs express tumor-associated antigens, and we show here a proof-of principle for using irradiated iPSCs in autologous anti-tumor vaccines. In a prophylactic setting, iPSC vaccines prevent tumor growth in syngeneic murine breast cancer, mesothelioma, and melanoma models. As an adjuvant, the iPSC vaccine inhibited melanoma recurrence at the resection site and reduced metastatic tumor load, which was associated with fewer Th17 cells and increased CD11b+GR1hi myeloid cells. Adoptive transfer of T cells isolated from vaccine treated-tumor-bearing mice inhibited tumor growth in unvaccinated recipients, indicating that the iPSC vaccine promotes an antigen-specific anti-tumor T cell response. Our data suggest a generalizable strategy for multiple types of cancer that could prove highly valuable in clinical immunotherapy.

show abstract

Section: Star Methodsmentioning

confidence: 99%

Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other methods used for cardiac modeling so far include the use of Sendai virus vectors (Churko et al, 2013), which obviate translational issues associated with transgene integration into the host cell’s genome. Additionally, the use of episomal plasmids (Burridge et al, 2011), co-MIP (Diecke et al, 2015), microRNAs (Li et al, 2011), and direct protein delivery (Zhou et al, 2009) have all been shown to be capable of producing iPSCs that can be differentiated into beating cardiomyocytes.…”

Section: Introduction: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening

Smith

Macadangdang

Leung

et al. 2017

Biotechnology Advances

130

103

View full text Add to dashboard Cite

Improved methodologies for modeling cardiac disease phenotypes and accurately screening the efficacy and toxicity of potential therapeutic compounds are actively being sought to advance drug development and improve disease modeling capabilities. To that end, much recent effort has been devoted to the development of novel engineered biomimetic cardiac tissue platforms that accurately recapitulate the structure and function of the human myocardium. Within the field of cardiac engineering, induced pluripotent stem cells (iPSCs) are an exciting tool that offer the potential to advance the current state of the art, as they are derived from somatic cells, enabling the development of personalized medical strategies and patient specific disease models. Here we review different aspects of iPSC-based cardiac engineering technologies. We highlight methods for producing iPSC-derived cardiomyocytes (iPSC-CMs) and discuss their application to compound efficacy/toxicity screening and in vitro modeling of prevalent cardiac diseases. Special attention is paid to the application of micro- and nano-engineering techniques for the development of novel iPSC-CM based platforms and their potential to advance current preclinical screening modalities.

show abstract

“…Furthermore, the 4-in-1 CoMiP vector is a highly efficient, integration-free, and cost-effective methodology applicable for hiPSC reprograming in a wide variety of cell types (57).…”

Section: Human Induced Pluripotent Stem Cellsmentioning

confidence: 99%

Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine

Matsa

Ahrens

2016

Physiological Reviews

Self Cite

View full text Add to dashboard Cite

Human induced pluripotent stem cells (hiPSCs) have revolutionized the field of human disease modeling, with an enormous potential to serve as paradigm shifting platforms for preclinical trials, personalized clinical diagnosis, and drug treatment. In this review, we describe how hiPSCs could transition cardiac healthcare away from simple disease diagnosis to prediction and prevention, bridging the gap between basic and clinical research to bring the best science to every patient.

show abstract

Novel codon-optimized mini-intronic plasmid for efficient, inexpensive and xeno-free induction of pluripotency

Cited by 55 publications

References 45 publications

Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo

Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo

Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening

Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine

Contact Info

Product

Resources

About